Chronic Graft Versus Host Disease Clinical Trials

25 recruitingLast updated: June 17, 2026

There are 25 actively recruiting chronic graft versus host disease clinical trials across 33 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Seattle, Washington, United States, Boston, Massachusetts, United States, Madrid, Spain. Updated daily from ClinicalTrials.gov.


Chronic Graft Versus Host Disease Trials at a Glance

25 actively recruiting trials for chronic graft versus host disease are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 16 trials, with the heaviest enrollment activity in Seattle, Boston, and Madrid. Lead sponsors running chronic graft versus host disease studies include Incyte Corporation, Fred Hutchinson Cancer Center, and Dana-Farber Cancer Institute.

Browse chronic graft versus host disease trials by phase

Treatments under study

About Chronic Graft Versus Host Disease Clinical Trials

Looking for clinical trials for Chronic Graft Versus Host Disease? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Graft Versus Host Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Graft Versus Host Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 2

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Lung DiseasesBronchiolitis Obliterans SyndromeChronic Graft Versus Host Disease+1 more
Dana-Farber Cancer Institute45 enrolled6 locationsNCT05922761
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting
Phase 2

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

Chronic Graft Versus Host Disease
Sanofi37 enrolled33 locationsNCT07116031
Recruiting
Phase 2

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center82 enrolled5 locationsNCT05996627
Recruiting
Phase 2

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

Chronic Graft Versus Host Disease
Incyte Corporation60 enrolled41 locationsNCT07124078
Recruiting
Phase 3

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease
Incyte Corporation240 enrolled122 locationsNCT06585774
Recruiting
Not Applicable

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

Acute Graft Versus Host DiseaseHematopoietic and Lymphatic System NeoplasmChronic Graft Versus Host Disease
Fred Hutchinson Cancer Center45 enrolled1 locationNCT07535008
Recruiting
Phase 2

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease
Syndax Pharmaceuticals296 enrolled121 locationsNCT04710576
Recruiting

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center300 enrolled10 locationsNCT04431479
Recruiting
Phase 2

A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT

Chronic Graft Versus Host DiseaseGraft vs Host Disease
WeiShi30 enrolled1 locationNCT07606703
Recruiting
Phase 2

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

Chronic Graft Versus Host DiseasecGVHD
University of Miami49 enrolled1 locationNCT06663722
Recruiting
Phase 2

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Chronic Graft Versus Host Disease
Northside Hospital, Inc.25 enrolled1 locationNCT06046248
Recruiting
Phase 2

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center50 enrolled3 locationsNCT07011810
Recruiting
Phase 2

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease
Incyte Corporation120 enrolled70 locationsNCT06388564
Recruiting
Not Applicable

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

Acute Graft Versus Host DiseaseChronic Graft Versus Host DiseaseGraft vs Host Disease
Dana-Farber Cancer Institute36 enrolled2 locationsNCT05236062
Recruiting

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

Chronic Graft Versus Host Disease
M.D. Anderson Cancer Center8 enrolled1 locationNCT07127926
Recruiting
Phase 1Phase 2

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

Chronic Graft Versus Host Disease
Incyte Corporation30 enrolled9 locationsNCT06843408
Recruiting
Phase 1

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Chronic Graft Versus Host Disease
Stefanie Sarantopoulos, MD, PhD.30 enrolled1 locationNCT06233110
Recruiting
Phase 1

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease
Qurient Co., Ltd.18 enrolled8 locationsNCT07138196
Recruiting
Phase 2

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphatic System NeoplasmChronic Graft Versus Host Disease
Mayo Clinic40 enrolled1 locationNCT06271616